Sector News

India’s Strides Arcolab to buy Shasun Pharma for $200 mln in all-stock deal

September 29, 2014
Life sciences
(Reuters) – India’s Strides Arcolab Ltd has agreed to buysmaller rival Shasun Pharmaceuticals Ltd in an all-stock deal, valued at about $200 million, to bolster its generic medicine and drug ingredient businesses.
 
Shasun, which has a market value of $193.5 million, makes drug ingredients and finished medicines, as well as provides contract research and manufacturing services. It supplies to North America, Europe, Asia and Latin America.
 
The acquisition is expected to close by June 2015, and is subject to regulatory approvals, the companies said in a stock exchange filing on Monday.
 
The deal is part of a consolidation in the pharmaceutical sector, which was expected to happen after Sun Pharmaceutical Industries Ltd agreed in April to buy local rival Ranbaxy Laboratories Ltd for $3.2 billion to create the world’s fifth largest maker of generic drugs.
 
Under the terms of the deal, Shasun shareholders will get five Strides shares for every 16 held in Shasun, the companies said in a joint statement. That values Shasun at roughly $200 million based on the stocks’ closing price on Friday.
 
The combined entity, in which Shasun shareholders will own 26 percent, will have 12 manufacturing plants and a pipeline of over 100 products, said the statement.
 
In February last year, Strides sold its injectable drugs business to U.S. firm Mylan Inc for $1.6 billion.
 
Shares in Strides rose as much as 12.8 percent to 724 rupees after the deal announcement on Monday, while Shasun ended down 0.3 percent at 196.15 rupees. The main Mumbai market index fell 0.1 percent. (Reporting by Zeba Siddiqui; additional reporting by Devidutta Tripathy; Editing by Sumeet Chatterjee and Miral Fahmy)

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend